Works matching DE "RITONAVIR"

Results: 1051

Nirmatrelvir plus ritonavir in COVID-19: a profile of its use.

Published in:

Drugs & Therapy Perspectives, 2023, v. 39, n. 2, p. 41, doi. 10.1007/s40267-022-00971-1

By:

Blair, Hannah A.

Publication type:

Article

Electrophysiological features and multimodal imaging in ritonavir-related maculopathy.

Published in:

Documenta Ophthalmologica, 2017, v. 135, n. 3, p. 241, doi. 10.1007/s10633-017-9612-z

By:

Faure, Céline;
Paques, Michel;
Audo, Isabelle

Publication type:

Article

Hydroxychloroquine and ritonavir for COVID-19 infection: a possible synergic toxicity for retinal pigmented epithelium.

Published in:

2020

By:

Romano, Mario R.;
Raimondi, Raffaele;
Montericcio, Alessio;
Allegrini, Davide

Publication type:

Letter

Pharmacokinetics of nirmatrelvir/ritonavir and the drug-drug interaction with calcineurin inhibitor in renal transplant recipients.

Published in:

European Journal of Clinical Pharmacology, 2024, v. 80, n. 8, p. 1219, doi. 10.1007/s00228-024-03691-9

By:

Xu, Xueyin;
Zhang, Huanxi;
Liu, Longshan;
Fu, Qian;
Wu, Chenglin;
Lin, Xiaobin;
Tang, Kejing;
Wang, Changxi;
Chen, Pan

Publication type:

Article

COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed.

Published in:

European Journal of Clinical Pharmacology, 2022, v. 78, n. 10, p. 1697, doi. 10.1007/s00228-022-03370-7

By:

Yalcin, Nadir;
Allegaert, Karel

Publication type:

Article

Evaluation of the effects of atazanavir-ritonavir on the pharmacokinetics of lumefantrine in patients living with HIV in Lagos University Teaching Hospital, South-Western Nigeria.

Published in:

European Journal of Clinical Pharmacology, 2021, v. 77, n. 9, p. 1341, doi. 10.1007/s00228-021-03116-x

By:

Usman, Sikiru Olatunji;
Oreagba, Ibrahim Adekunle;
Kadri, Michael Rotimi;
Adewumi, Ololade Oluwatosin;
Akinyede, Akinwumi;
Agbaje, Esther Oluwatoyin;
Abideen, Ganiyu;
Busari, AbdulWasiu Adeniyi;
Hassan, Olayinka Olaiwola;
Akinleye, Moshood Olusola;
Akanmu, Alani Sulaimon

Publication type:

Article

Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model.

Published in:

European Journal of Clinical Pharmacology, 2021, v. 77, n. 4, p. 607, doi. 10.1007/s00228-020-03036-2

By:

Stillemans, Gabriel;
Belkhir, Leila;
Vandercam, Bernard;
Vincent, Anne;
Haufroid, Vincent;
Elens, Laure

Publication type:

Article

Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials

Published in:

European Journal of Clinical Pharmacology, 2019, v. 75, n. 2, p. 207, doi. 10.1007/s00228-018-2566-6

By:

Shuster, Diana L.;
Menon, Rajeev M.;
Ding, Bifeng;
Khatri, Amit;
Li, Hong;
Cohen, Eric;
Jewett, Melissa;
Cohen, Daniel E.;
Zha, Jiuhong

Publication type:

Article

Darunavir concentration in PBMCs may be a better indicator of drug exposure in HIV patients.

Published in:

European Journal of Clinical Pharmacology, 2018, v. 74, n. 8, p. 1055, doi. 10.1007/s00228-018-2464-y

By:

Nagano, Daisuke;
Araki, Takuya;
Yanagisawa, Kunio;
Ogawa, Yoshiyuki;
Gohda, Fumito;
Uchiumi, Hideki;
Handa, Hiroshi;
Nakamura, Tomonori;
Yamamoto, Koujirou

Publication type:

Article

Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban.

Published in:

European Journal of Clinical Pharmacology, 2018, v. 74, n. 6, p. 755, doi. 10.1007/s00228-018-2430-8

By:

Xu, Ruijuan;
Ge, Weihong;
Jiang, Qing

Publication type:

Article

Effect of hepatitis B and C clearance on atazanavir exposure.

Published in:

2015

By:

Gervasoni, Cristina;
Cattaneo, Dario;
Micheli, Valeria;
Cristo, Valentina;
Milazzo, Laura

Publication type:

Letter

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.

Published in:

European Journal of Clinical Pharmacology, 2014, v. 70, n. 10, p. 1173, doi. 10.1007/s00228-014-1732-8

By:

Song, Ivy;
Borland, Julie;
Chen, Shuguang;
Guta, Phyllis;
Lou, Yu;
Wilfret, David;
Wajima, Toshihiro;
Savina, Paul;
Peppercorn, Amanda;
Castellino, Stephen;
Wagner, David;
Hosking, Louise;
Mosteller, Michael;
Rubio, Justin;
Piscitelli, Stephen

Publication type:

Article

A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.

Published in:

European Journal of Clinical Pharmacology, 2013, v. 69, n. 11, p. 1939, doi. 10.1007/s00228-013-1556-y

By:

Morcos, Peter;
Chang, Linda;
Kulkarni, Rohit;
Giraudon, Mylene;
Shulman, Nancy;
Brennan, Barbara;
Smith, Patrick;
Tran, Jonathan

Publication type:

Article

Concentration effect relationship of CYP3A inhibition by ritonavir in humans.

Published in:

European Journal of Clinical Pharmacology, 2013, v. 69, n. 10, p. 1795, doi. 10.1007/s00228-013-1530-8

By:

Eichbaum, Christine;
Cortese, Marianna;
Blank, Antje;
Burhenne, Jürgen;
Mikus, Gerd

Publication type:

Article

Long-term Follow-up Liver Stiffness Results of Chronic Hepatitis C Patients Treated with Direct-acting Antivirals.

Published in:

Journal of Tepecik Education & Research Hospital / İzmir Tepecik Eğitim ve Araştırma Hastanesi Dergisi, 2023, v. 33, n. 1, p. 76, doi. 10.4274/terh.galenos.2022.68736

By:

Hakim, Gözde Derviş;
Tufan, Ayşe Gökçen

Publication type:

Article

The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.

Published in:

Turkish Journal of Medical Sciences, 2021, v. 51, n. 4, p. 1624, doi. 10.3906/sag-2012-189

By:

ÇINARKA, Halit;
GÜNLÜOĞLU, Gülşah;
ÇÖRTÜK, Mustafa;
YURT, Sibel;
KIYIK, Murat;
KOŞAR, Filiz;
TANRIVERDİ, Elif;
ARSLAN, Melih Akay;
BAYDİLİ, Kürşad Nuri;
KOÇ, Aysu Sinem;
ALTIN, Sedat;
ÇETİNKAYA, Erdoğan

Publication type:

Article

Antiviral treatment of COVID-19.

Published in:

Turkish Journal of Medical Sciences, 2020, v. 50, n. SI, p. 611, doi. 10.3906/sag-2004-145

By:

ŞİMŞEK YAVUZ, Serap;
ÜNAL, Serhat

Publication type:

Article

Drug-drug interaction between ensitrelvir and tacrolimus in a patient undergoing treatment for COVID-19: a case report.

Published in:

Journal of Pharmaceutical Health Care & Sciences, 2025, v. 11, n. 1, p. 1, doi. 10.1186/s40780-025-00411-y

By:

Miyata, Yuki;
Yamaguchi, Ryo;
Yamamoto, Takehito;
Kishida, Toshiyuki;
Ikeuchi, Kazuhiko;
Harada, Hiroaki;
Tsutsumi, Takeya;
Fujio, Keishi;
Takada, Tappei

Publication type:

Article

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?

Published in:

Antibiotics (2079-6382), 2022, v. 11, n. 2, p. 220, doi. 10.3390/antibiotics11020220

By:

Hung, Yuan-Pin;
Lee, Jen-Chieh;
Chiu, Chun-Wei;
Lee, Ching-Chi;
Tsai, Pei-Jane;
Hsu, I-Lin;
Ko, Wen-Chien

Publication type:

Article

Paxlovid (Nirmatrelvir and Ritonavir) Use in Pregnant and Lactating Woman: Current Evidence and Practice Guidelines—A Scoping Review.

Published in:

Vaccines, 2023, v. 11, n. 1, p. 107, doi. 10.3390/vaccines11010107

By:

Chourasia, Prabal;
Maringanti, Babu Sriram;
Edwards-Fligner, Morgan;
Gangu, Karthik;
Bobba, Aniesh;
Sheikh, Abu Baker;
Shekhar, Rahul

Publication type:

Article

Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?

Published in:

European Review for Medical & Pharmacological Sciences, 2021, v. 25, n. 5, p. 2435

By:

DALLOCCHIO, R. N.;
DESSÌ, A.;
DE VITO, A.;
DELOGU, G.;
SERRA, P. A.;
MADEDDU, G.

Publication type:

Article

Reply Letter – “Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis”.

Published in:

2021

By:

DE VITO, A.;
MADEDDU, G.

Publication type:

Letter to the Editor

Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis.

Published in:

European Review for Medical & Pharmacological Sciences, 2021, v. 25, n. 1, p. 549

By:

LU, J.-M.;
ZHOU, A.-F.;
ZHANG, X.-B.;
XU, H.;
WANG, X.-F.;
YE, Q.-F.;
SHANG, F.-N.;
HE, Y.-L.;
MA, S.-L.;
CUI, Y.-X.;
CHEN, R.-J.;
LI, X.-Y.;
ZHAI, X.-W.;
LI, Z.-P.

Publication type:

Article

A contemporary look at COVID-19 medications: available and potentially effective drugs.

Published in:

European Review for Medical & Pharmacological Sciences, 2020, v. 24, n. 17, p. 9188

By:

ALSHAERI, H. K.;
NATTO, Z. S.

Publication type:

Article

Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.

Published in:

European Review for Medical & Pharmacological Sciences, 2020, v. 24, n. 16, p. 8592

By:

VARGAS, M.;
SERVILLO, G.;
EINAV, S.

Publication type:

Article

Secondary Adrenal Insufficiency Due to the Co-Administration of Ritonavir and Inhaled Fluticasone Propionate: Case report.

Published in:

Sultan Qaboos University Medical Journal, 2017, v. 17, n. 3, p. 339, doi. 10.18295/squmj.2017.17.03.014

By:

Al-Maqbali, Ali;
Kamble, Bina;
Al-Qassabi, Salim;
Elgalib, Ali

Publication type:

Article

High Detection Rate of HIV Drug Resistance Mutations among Patients Who Fail Combined Antiretroviral Therapy in Manaus, Brazil.

Published in:

BioMed Research International, 2021, p. 1, doi. 10.1155/2021/5567332

By:

Chaves, Yury Oliveira;
Pereira, Flávio Ribeiro;
de Souza Pinheiro, Rebeca;
Batista, Diego Rafael Lima;
da Silva Balieiro, Antônio Alcirley;
de Lacerda, Marcus Vinicius Guimarães;
Nogueira, Paulo Afonso;
Guimarães, Monick Lindenmeyer

Publication type:

Article

"Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".

Published in:

Transplant Infectious Disease, 2023, v. 25, n. 2, p. 1, doi. 10.1111/tid.14037

By:

Belden, Katherine A.;
Yeager, Sarah;
Schulte, Jamie;
Cantarin, Maria P. Martinez;
Moss, Sean;
Royer, Tricia;
Coppock, Dagan

Publication type:

Article

Nanomaterials for Photocatalytic Degradations of Analgesic, Mucolytic and Anti-Biotic/Viral/Inflammatory Drugs Widely Used in Controlling SARS-CoV-2.

Published in:

Catalysts (2073-4344), 2022, v. 12, n. 6, p. N.PAG, doi. 10.3390/catal12060667

By:

Ebrahimi, Mahsa;
Akhavan, Omid

Publication type:

Article

Efficacy and Safety of Anti-SARS-CoV-2 Antiviral Agents and Monoclonal Antibodies in Patients with SLE: A Case-Control Study.

Published in:

Biomolecules (2218-273X), 2023, v. 13, n. 9, p. 1273, doi. 10.3390/biom13091273

By:

Ramirez, Giuseppe A.;
Gerosa, Maria;
Bellocchi, Chiara;
Arroyo-Sánchez, Daniel;
Asperti, Chiara;
Argolini, Lorenza M.;
Gallina, Gabriele;
Cornalba, Martina;
Scotti, Isabella;
Suardi, Ilaria;
Moroni, Luca;
Beretta, Lorenzo;
Bozzolo, Enrica P.;
Caporali, Roberto;
Dagna, Lorenzo

Publication type:

Article

Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia.

Published in:

HIV Medicine, 2017, v. 18, n. 10, p. 782, doi. 10.1111/hiv.12530

By:

Echeverría, P;
Bonjoch, A;
Puig, J;
Ornella, A;
Clotet, B;
Negredo, E

Publication type:

Article

Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection.

Published in:

HIV Medicine, 2017, v. 18, n. 7, p. 474, doi. 10.1111/hiv.12478

By:

Calza, L;
Colangeli, V;
Magistrelli, E;
Bussini, L;
Conti, M;
Ramazzotti, E;
Mancini, R;
Viale, P

Publication type:

Article

Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial.

Published in:

HIV Medicine, 2017, v. 18, n. 1, p. 5, doi. 10.1111/hiv.12386

By:

Girard, PM;
Antinori, A;
Arribas, JR;
Ripamonti, D;
Bicer, C;
Netzle‐Sveine, B;
Hadacek, B;
Moecklinghoff, C

Publication type:

Article

Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens.

Published in:

HIV Medicine, 2017, v. 18, n. 1, p. 21, doi. 10.1111/hiv.12388

By:

Armenia, D;
Di Carlo, D;
Maffongelli, G;
Borghi, V;
Alteri, C;
Forbici, F;
Bertoli, A;
Gori, C;
Giuliani, M;
Nicastri, E;
Zaccarelli, M;
Pinnetti, C;
Cicalini, S;
D'Offizi, G;
Ceccherini‐Silberstein, F;
Mussini, C;
Antinori, A;
Andreoni, M;
Perno, CF;
Santoro, MM

Publication type:

Article

Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.

Published in:

HIV Medicine, 2016, v. 17, n. 9, p. 643, doi. 10.1111/hiv.12366

By:

Crauwels, HM;
Kakuda, TN;
Ryan, B;
Zorrilla, C;
Osiyemi, OO;
Yasin, S;
Brown, K;
Verboven, P;
Hillewaert, V;
Baugh, B

Publication type:

Article

Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial.

Published in:

HIV Medicine, 2016, v. 17, n. 8, p. 605, doi. 10.1111/hiv.12362

By:

Lee, FJ;
Monteiro, P;
Baker, D;
Bloch, M;
Roth, N;
Finlayson, R;
Moore, R;
Hoy, J;
Martinez, E;
Carr, A

Publication type:

Article

PEPDar: A randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis.

Published in:

HIV Medicine, 2016, v. 17, n. 6, p. 453, doi. 10.1111/hiv.12363

By:

Fätkenheuer, G;
Jessen, H;
Stoehr, A;
Jung, N;
Jessen, AB;
Kümmerle, T;
Berger, M;
Bogner, JR;
Spinner, CD;
Stephan, C;
Degen, O;
Vogelmann, R;
Spornraft‐Ragaller, P;
Schnaitmann, E;
Jensen, B;
Ulmer, A;
Kittner, JM;
Härter, G;
Malfertheiner, P;
Rockstroh, J

Publication type:

Article

Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.

Published in:

HIV Medicine, 2016, v. 17, n. 5, p. 358, doi. 10.1111/hiv.12348

By:

Arribas, JR;
Girard, P‐M;
Paton, N;
Winston, A;
Marcelin, A‐G;
Elbirt, D;
Hill, A;
Hadacek, MB

Publication type:

Article

The Intelence aNd pRezista Once A Day Study ( INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.

Published in:

HIV Medicine, 2015, v. 16, n. 5, p. 288, doi. 10.1111/hiv.12211

By:

Ruane, PJ;
Brinson, C;
Ramgopal, M;
Ryan, R;
Coate, B;
Cho, M;
Kakuda, TN;
Anderson, D

Publication type:

Article

Low concordance and resistance mutation emergence in the HIV protease gene among circulating and cell-associated viruses at viral replication episodes during darunavir/ritonavir monotherapy.

Published in:

HIV Medicine, 2015, v. 16, n. 1, p. 57, doi. 10.1111/hiv.12170

By:

Torres‐Cornejo, A;
Benmarzouk‐Hidalgo, OJ;
Gutierrez‐Valencia, A;
Ruiz‐Valderas, R;
Viciana, P;
López‐Cortés, LF

Publication type:

Article

Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.

Published in:

HIV Medicine, 2014, v. 15, n. 10, p. 604, doi. 10.1111/hiv.12164

By:

Else, LJ;
Jackson, V;
Brennan, M;
Back, DJ;
Khoo, SH;
Coulter‐Smith, S;
Lambert, JS

Publication type:

Article

Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen.

Published in:

HIV Medicine, 2014, v. 15, n. 9, p. 547, doi. 10.1111/hiv.12144

By:

Jarrin, I;
Hernández‐Novoa, B;
Alejos, B;
Santos, I;
Lopez‐Aldeguer, J;
Riera, M;
Gutiérrez, F;
Rubio, R;
Antela, A;
Blanco, JR;
Moreno, S

Publication type:

Article

Pharmacokinetics and efficacy of darunavir/ritonavir once daily in virologically suppressed, treatment-experienced HIV-infected children.

Published in:

HIV Medicine, 2014, v. 15, n. 8, p. 511, doi. 10.1111/hiv.12163

By:

Chokephaibulkit, K;
Rungmaitree, S;
Phongsamart, W;
Lappra, K;
Wittawatmongkol, O;
Kongstan, N;
Cressey, TR

Publication type:

Article

Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.

Published in:

HIV Medicine, 2014, v. 15, n. 7, p. 417, doi. 10.1111/hiv.12129

By:

Macías, J;
Recio, E;
Márquez, M;
García, C;
Jiménez, P;
Merino, D;
Muñoz, L;
Pasquau, J;
Ojeda, G;
Bancalero, P;
Chueca, N;
Pineda, JA

Publication type:

Article

A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction.

Published in:

HIV Medicine, 2014, v. 15, n. 5, p. 301, doi. 10.1111/hiv.12118

By:

Baril, J;
Conway, B;
Giguère, P;
Ferko, N;
Hollmann, S;
Angel, JB

Publication type:

Article

Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.

Published in:

HIV Medicine, 2014, v. 15, n. 1, p. 50, doi. 10.1111/hiv.12047

By:

Zorrilla, CD;
Wright, R;
Osiyemi, OO;
Yasin, S;
Baugh, B;
Brown, K;
Coate, B;
Verboven, P;
Mrus, J;
Falcon, R;
Kakuda, TN

Publication type:

Article

Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.

Published in:

HIV Medicine, 2013, v. 14, n. 7, p. 421, doi. 10.1111/hiv.12019

By:

Kakuda, TN;
DeMasi, R;
Delft, Y;
Mohammed, P

Publication type:

Article

Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.

Published in:

HIV Medicine, 2013, v. 14, n. 7, p. 437, doi. 10.1111/hiv.12024

By:

Sension, M;
Cahn, P;
Domingo, P;
Hodder, S;
Opsomer, M;
Lathouwers, E;
Van de Casteele, T;
Tomaka, F

Publication type:

Article

Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.

Published in:

HIV Medicine, 2013, v. 14, n. 7, p. 401, doi. 10.1111/hiv.12017

By:

Dumond, JB;
Adams, JL;
Prince, HMA;
Kendrick, RL;
Wang, R;
Jennings, SH;
Malone, S;
White, N;
Sykes, C;
Corbett, AH;
Patterson, KB;
Forrest, A;
Kashuba, ADM

Publication type:

Article

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

Published in:

HIV Medicine, 2013, v. 14, n. 1, p. 49, doi. 10.1111/j.1468-1293.2012.01060.x

By:

Orkin, C;
DeJesus, E;
Khanlou, H;
Stoehr, A;
Supparatpinyo, K;
Lathouwers, E;
Lefebvre, E;
Opsomer, M;
Van de Casteele, T;
Tomaka, F

Publication type:

Article